Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Support side: 10% holder buying, Insider buying cluster — insiders or holders bought while this setup is live; see the timeline.
Radar 87 (high attention) · dilution pressure high · listing risk high · governance risk high · runway 0.3 mo · strongest signal: MVLS deficiency (Jul 31, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 138 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Late filing (NT) | NT 10-Q filed 2026-08-14 filing | 49 |
| Aug 14, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-14 filing | 37 |
| Aug 14, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-08-14 (accepted 16:42 ET) filing | 26 |
| Aug 14, 2026 | · Form 4 burst | 6 Form 4 filings in 30 days filing | 15 |
| Aug 13, 2026 | ▲ Insider buying cluster | 8 open-market buys by 1 insider(s) (~$36,946) in 30d: HRT FINANCIAL LP 5,[email protected] 2026-08-12; HRT FINANCIAL LP 4,[email protected] 2026-08-10; HRT FINANCIAL LP [email protected] 2026-08-06; HRT FINANCIAL LP 14,[email protected] 2026-08-03 filing | 42 |
| Aug 13, 2026 | ▲ 10% holder buying | 10% holder open-market purchases: HRT FINANCIAL LP 5,[email protected]; HRT FINANCIAL LP 4,[email protected]; HRT FINANCIAL LP [email protected]; HRT FINANCIAL LP 14,[email protected]; HRT FINANCIAL LP 1,[email protected]; HRT FINANCIAL LP 1,[email protected]; HRT FINANCIAL LP 8,[email protected] filing | 42 |
| Aug 13, 2026 | ▼ Insider selling cluster | 4 open-market sales by 1 insider(s) (~$41,107) in 30d filing | 32 |
| Jul 31, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-07-31 filing | 51 |
| Jul 31, 2026 | ▼ Restatement (non-reliance) | “nonreliance” language in 8-K (EX-2.1) filed 2026-07-31 filing | 38 |
| Jul 31, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-31 (accepted 16:56 ET) filing | 37 |
| Jul 31, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-07-31 filing | 37 |
| Jul 31, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-07-31 filing | 32 |
| Jul 27, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-27 (accepted 06:08 ET) filing | 28 |
| Mar 31, 2026 | ▼ Runway < 6 months | ~0.3 months runway: liquidity $375,000 as of 2026-03-31, burn $16,248,000/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing | 45 |
| Mar 31, 2026 | ▼ Negative equity | Stockholders' equity $-28,198,000 as of 2026-03-31 filing | 31 |
| Mar 31, 2026 | ▼ Near $5M MVLS floor | Public float $1,300,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 31 |
| Mar 31, 2026 | ▼ Cash < current liabilities | Liquidity $375,000 vs current liabilities $29,020,000 filing | 21 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →